Microsatellite analyses show that self-reported ethnicity often correlates poorly with true genetic ancestry. As unknown ancestral differences could potentially have an impact on transplant outcome, we developed an average allele length discrepancy (AALD) score to assess allele length discrepancy between donor/recipient (D/R) using microsatellites analysed routinely in post-transplant chimeric assessment. This was then compared with outcome in a homogeneously treated cohort of pediatric patients undergoing high-resolution sibling or matched unrelated donor transplantation for acute lymphoblastic leukemia (ALL). AALD scores formed a numeric continuum ranging from 0 to 1.4 (median 0.76) for sibling pairs and 0.8-2.17 (median 1.6) for high-resolution matched unrelated donor (HR-MUD) pairs. There was a trend for worse OS with increasing AALD score, which reached statistical significance above a threshold of 1.7 for OS. Patients whose transplants had an AALD score of ⩾ 1.8 had a risk of non-relapse mortality 4.9 times greater (P = 0.025) and relapse risk three times greater (P = 0.058) than those scoring o 1.8. This approach will now be explored in a Centre International for Blood and Marrow Transplantation Research (CIBMTR) study of 750 D/R pairs across all disease groups; if confirmed, it has the potential to improve donor selection for patients with multiple prospective donors.
INTRODUCTION
Geographic distance has been shown to correlate with genetic distance (GD) between ancestral populations. 1 Registries collect data on the ethnic origin of donor/recipient (D/R) pairs so as to determine whether ethnic mismatch has an impact on transplant outcome. However, self-reported ethnic origin or other morphological features, such as skin color, are poor predictors of true genetic ancestral origin. 2 A marker for genetic ancestral differentiation (GAD) that is independent of self-reported ethnicity and reflects ancestral differences both within and between populations may therefore be of significance in transplantation studies.
Microsatellite analysis offers an alternative means of examining the effect of ancestry, as it is thought that all humans derive from African ancestors and that STR microsatellite allele lengths have drifted with GD from these ancestors. 1, [3] [4] [5] This occurs predominantly by mutation due to single step, strand-slippage replication (SSR). 3, 6, 7 Thus, in general, a raised microsatellite length discrepancy between two individuals reveals an increased number of SSR mutation events separating their ancestors, providing a measure for GAD. 5 Although homoplasty (alleles of same length coming from divergent ancestries) may be a confounder, the use of multiple microsatellite loci overcomes this possible constraint. 6 Interpopulation variability as measured by GD is reflected in gene and protein polymorphisms, 1, 4, 8 which may affect transplant outcome (for example, minor histocompatibility antigens and cytokine polymorphisms). [9] [10] [11] [12] This may explain the higher severity of acute GVHD and lower OS seen in matched sibling donor (MSD) transplants where donors (D) and recipients (R) displayed a tally of more than 10 (from 15) microsatellite locus mismatches. 13 We hypothesized that a D/R weighted average allele length discrepancy (AALD) score calculated from 30 allelic pairs using 15 highly informative microsatellite loci (which is more comparable to microsatellite analysis from anthropological GD studies) might provide a more accurate readout of GAD than a microsatellite mismatch tally or self-reported ethnicity. In order to interrogate this, we examined the relationship to outcome in a population of homogeneously treated children who underwent MSD or 10/10 high-resolution matched unrelated donor (HR-MUD) haematopoietic SCT (HSCT) for ALL.
MATERIALS AND METHODS

Patient selection
Data were assessed on 61 consecutive patients under the age of 18 who underwent high-resolution HLA-*A,*B,*C,*DRB1,*DQB1-matched MSD or HR-MUD HSCT for ALL at the Bristol Royal Hospital for Children between 2004 and 2010. Fifty-four of these high-resolution HLA-matched patients have been previously reported in detail.
14 This research was approved to meet NHS Blood and Transplant research group governance requirements. All patients had been microsatellite-profiled for post-transplant chimerism studies.
STR profiling
We selected the PROMEGA, PowerPlex16 system that permits coamplification and three-color detection of 15 microsatellite loci in a single PCR amplification. Methodology was as described by the Eurochimera consortium. 15 Calculation of AALD scores for D/R pairs In order to have a consistent and comparable approach for each locus, identical allele lengths shared between D and R were assigned a length difference of zero. Otherwise, the shorter allele of the donor was paired with the shorter allele of the recipient and the length discrepancy was determined. This was repeated for the larger alleles. Microsatellite repeat unit discrepancy for each pair was calculated and the average microsatellite repeat unit length discrepancy calculated for all 30 allele pairs. The number generated was termed the AALD score; it correlates with the absolute number of SSR mutations observed to separate the D/R ancestries (Table 1) .
Data analysis
We have previously reported single and multivariate analyses on the following covariates in this single centre cohort of pediatric ALL transplants: disease status, age, HLA match grade/relationship, patient/ donor CMV status, stem cell source, days to engraftment, sex combinations, GVHD and changes to pre-transplant conditioning protocol, using logistic regression and the Cox proportional hazards models. 14 In that study the high-resolution HLA-matched patient cohort did not differ significantly from the other patients for the above listed covariates. Only D/R relationship, high-resolution HLA match grade and disease status at the time of transplantation were shown statistically to significantly affect transplant outcome.
As all transplants reported in this study were 10/10 HLA-matched, only disease status at transplantation and relationship of D/R were considered as confounders for analysis with AALD values. Univariate proportional hazards survival models were built to assess the effect that relationship (that is, MSD versus HR-MUD), remission status at transplant and dichotomised threshold AALD values had on non-relapse mortality (NRM) and disease relapse as competing risks for transplant outcomes (Table 2) . Kaplan-Meier estimates of survival compared 2-year OS in MSD vs MUD transplants for AALD scores at four threshold values (1.4, 1.6, 1.8 and 1.9; Figure 1 ).
RESULTS AND DISCUSSION
Despite longstanding expectations that receiving stem cells from an ethnically mismatched donor could have an impact on transplant outcome, such an effect has never been demonstrated convincingly. In our study we suggest that microsatellite analysis enables renewed interrogation of issues concerning ancestral differences. Agrawal and Khan 16 have shown that just five selected microsatellite loci were sufficiently discriminating to differentiate 21 world populations and to construct human phylogenetic trees using microsatellite allelic length variability. In this study, we have utilized 15 microsatellite profiles (those routinely performed for assessment of chimerism in our centre) to look for an influence of GAD on transplant outcome.
The resultant D/R AALD scores formed a numeric continuum ranging from 0 to 1.4 (median 0.76) for sibling pairs and 0.8-2.17 (median 1.6) for HR-MUD pairs. In univariate analysis, neither remission status at transplant nor donor type (MSD vs HR-MUD) significantly affected NRM or relapse. By contrast, NRM and relapse reached statistical significance in proportionate hazard models at threshold AALD scores of 1.8 and 1.9, respectively, and for OS at an AALD score of 1.7 (Table 2) .
At the outset of this project we hypothesised that the effect of highly discrepant D/R GAD would most likely have an impact on NRM rather than relapse rates-if differences reflected by AALD scores were correlated with protein polymorphisms affecting immune processes (for example, minor histocompatibility antigens and cytokine responses) or pathogen handling. We were also concerned that identification of such effects might be hampered by Alemtuzumab T-cell depletion in the HR-MUD transplants and a Abbreviations: AALD = average allele length discrepancy. List of the donor and recipient allele sizes observed for each microsatellite locus in base pairs and their chromosomal location. From this, the allele size difference in repeat units is derived and the AALD value is calculated. This example was selected from the patient cohort reported in this study.
Microsatellite discrepancy and all transplant survivals J Harvey et al low resultant rate of GVHD (grade 2-4 acute GVHD 5%, chronic GVHD 0%). 17 The incidence of NRM for all patients was 8/61 (13%) and relapse 13/61 (21%) over 2 years, compared with 24% NRM and 25% relapse rates at 3 years in a larger multicentre series of Alemutuzmab-based unrelated donor (UD) transplants for childhood ALL. 17 However, both NRM and risk of relapse were found to be markedly affected by higher AALD scores: for example, NRM was 4.9 times greater for AALD ⩾ 1.8 compared with o 1.8 (P = 0.025), whereas the risk of relapse was three times (P = 0.058) and overall mortality was 3.6 times greater (P = 0.004). (Table 2 ). The causes of NRM were diverse, including multiorgan failure (one), pneumonitis (one), pulmonary embolism (one), GVHD (two), Abbreviations: AALD = average allele length discrepancy; CI = confidence interval; HR = hazard ratios; HR-MUD = high-resolution matched unrelated donor; NRM = non-relapse mortality; REL = relapse. Incidence of NRM in the sample is 8/61 (13%). Incidence of REL in the sample is 13/61 (21%). Note: the HRs for each of NRM and REL are the results of separate models. For AALD, each threshold represents a separate model. The results show that there is insufficient evidence to conclude that remission type or donor-recipient relationship have any effect on survival probability. However, AALD, when dichotomised at the 1.8, 1.9 or 2.0 thresholds, does appear to affect survival probability. with dichotomised survival values of (a) 63% (n = 27) vs 71% (n = 14; P = 0.68); (b) 57% (n = 21) vs 75%(n = 20; P = 0.27); (c) 43% (n = 14) vs 77% (n = 27; P = 0.02) and (d) 33% (n = 9) vs 75% (n = 32; P = 0.004), respectively.
colitis(one), viral infection (one), liver failure (one); no single cause predominated. It is therefore not possible to speculate further on underlying mechanisms, which may be responsible. We did not HLA-DPB1 type in our donor-recipient pairs, but we have considered this as a possible confounder for our results. Two studies of 5929 and 8539 transplants showed lower overall hazard ratio for DPB1-mismatched transplants at 1.09 and 1.15, respectively. 18, 19 We believe that, in a study of only 61 transplants, any effect due to HLA-DPB1 mismatching on OS would not reach detectable statistical significance and could not account for the association of NRM and relapse with higher AALD values that we report.
It is also unclear why relapse rate correlated with AALD score. However, it is known that post-transplant relapse risk can vary in different populations, suggesting genetic influences that may correlate with this score. One recent study of 4335 T-replete unrelated donor transplant pairs showed that Japanese patients had significantly lower levels of post-transplant relapse than White, African or Hispanic Americans, despite a lower incidence of all grades of GVHD and hence expectation of a reduced GVL effect. 20 Genome-wide array analysis has also been used to distinguish three Hispanic ancestral populations (Native American, African and European) and to show that the relative contribution of European or Native American ancestry had a statistically significant impact on age at diagnosis. 21 Differences in the KIR genes and their HLA ligands in childhood ALL may be one factor that contributes to differences in the frequency of ALL between Hispanic and non-Hispanic populations. 22 It may be that patients receiving highly AALD-discrepant grafts are opened up to some of these genetically/ancestrally related, but so far poorly understood, risk factors.
There are many caveats to these findings, which are based on univariate analysis of single centre transplants in one disease where 95% of D/R pairs were reported to be of Caucasian ethnicity. Furthermore, only 21% of MUD D/R pairs had an AALD score of ⩾ 1.8, with a decrement in the survival of 34% (see Figure 1) . Therefore, if alternative donors with AALD scores of o1.8 could have been sourced for all patients (which is unlikely), the effect on survival for the whole cohort would have been o10%. The effect that we report is, however, likely to be both more powerful and more relevant when applied to more ancestrally admixed populations. In order to investigate this, a Centre for International Blood and Marrow Research study of 4750 National Marrow Donor Program (NMDP) transplant pairs has been approved (CIBMTR, project no. IB13-04).
In summary, in a population of children transplanted homogeneously for a single malignant disease, we have shown a statistically significant association between a score for microsatellite discrepancy and outcome in terms of both relapse and NRM. If confirmed in other diseases and larger pediatric and adult studies, AALD testing could potentially allow improved selection of HLA high-resolution MUD donors for patients for whom multiple potential donors are available.
